Viewing Study NCT07038369


Ignite Creation Date: 2025-12-24 @ 11:11 PM
Ignite Modification Date: 2026-01-21 @ 7:50 AM
Study NCT ID: NCT07038369
Status: RECRUITING
Last Update Posted: 2025-12-09
First Post: 2025-06-18
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Sponsor: Atavistik Bio, Inc
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Advanced Solid Tumors View
None Breast Cancer View
None Breast Carcinoma View
None Breast Neoplasms View
None ER Positive Breast Cancer View
None Cervical Cancers View
None Cervical Neoplasms View
None Cervical Carcinoma View
None Triple Negative Breast Cancer View
None Gynecologic Cancers View
None Gynecologic Neoplasm View
None Endometrial Cancer View
None Endometrial Neoplasm View
None Endometrial Carcinoma (EC) View
None Fallopian Cancer View
None Ovarian Carcinoma View
None Ovarian Cancer View
None Ovarian Neoplasms View
None Prostate Cancers View
None Prostate Carcinoma View
None Solid Tumors View
None Neoplasms View
None Neoplasms by Site View
None Breast Diseases View
None Uterine Neoplasms View
None Genital Neoplasms, Female View
None Urogenital Neoplasms View
Keywords:

Keywords

Keyword Brief Keyword Text View
None AKT mutation View
None Mutant AKT View
None AKT1 mutation View
None AKT mutant View
None Gynecologic carcinoma View
None Fallopian Carcinoma View
None Fallopian Neoplasm View
None HR positive breast View
None AKT Gene Mutation View
None AKT1 E17K View